Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1995-06-07
1997-06-24
Mosley, Terressa
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
424490, 424493, 427212, 42721334, 42721336, 428402, 4284022, 42840221, 42840224, 428403, A61K 914
Patent
active
056415150
ABSTRACT:
A controlled release pharmaceutical formulation comprises nanoparticles formed of a biodegradable polycyanoacrylate polymer in which insulin is entrapped, the insulin being complexed to the polycyanoacrylate. These particles are capable of releasing bioactive insulin in vivo at a slower release rate than nanoparticles in which the insulin is free. The formulation may comprise a mixture of nanoparticles in which the insulin is free and nanoparticles in which it is complexed, so as to obtain the desired release profile. The nanoparticles have a preferred loading of 15-25% w/v insulin and a preferred size of 100-400 nm. Administration may be oral or parenteral, and for oral administration, an enteric coating may be provided to target release to the small intestine. Complexing of the insulin is achieved by the polymerisation of cyanoacrylate monomer in the presence of insulin at a low pH, preferably at about pH=2.
REFERENCES:
Al Khouri, N. et al., Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules, Int. J. Pharm., 28:125-32 (1986).
Couvreur, P. et al., Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties, J. Pharm. Pharmacol., 31;331-2 (1979).
Guise, V., et al., Vidarabine-Loaded Nanoparticles: A Physicochemical Study, Pharmaceutical Res., 7:736-41 (1990).
Douglas, S. et al., Particle Size and Size Distribution of Poly(butyl 2-cyanoacylate) Nanoparticles J. Colloid Interface Science, 103: 154-63 (1985).
Tasset, Ch., et al., Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin, J. of Controlled Release, 33:23-30 (1995).
Kattan, Joseph, et. al, Phase I Clinical Trial and Pharmacokinetic Evaluation of Doxorubicin Carried by Polyisohexylcyanoacrylate Nanoparticles, Investigational New Drugs, 10: 191-199 (1992).
Vansnick, L. et al, Molecular Weights of Free and Drug-Loaded Nanoparticles, Pharmaceutical Research, 36-41 (1985).
Guzman, M. et. al., Formation and Characterisation of Cyclosporin-Loaded Nanoparticles, Pharm. Sciences, 82, 498-502 (1993).
Douglas, et al., Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. I. Influence of physicochemical factors,, J. Colloid and Interface Science, 101: 149-58 (1984).
Douglas, et al., Poly(butyl 2-cyanoacrylate0 nanoparticles with differing surface charges, J. of Controlled Release, 3: 15-23 (1986).
Damge, C. et al., New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier, Diabetes, 37:246(51) (1988).
Lowe, P. et al., Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats, J. Pharma. Pharmacol., 46;547-52 (1994).
Gautier, J. et al., Biodegradable nanoparticles for subcutaneous administration of growth hormone releasing factor (hGRF) J. Controlled Release, 20:67-77 (1992).
Elan Corporation, plc
Mosley Terressa
Severson Mary L.
LandOfFree
Controlled release biodegradable nanoparticles containing insuli does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release biodegradable nanoparticles containing insuli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release biodegradable nanoparticles containing insuli will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-147839